Modified Conditioning Regimen for CML-BP

NCT07259161 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

CML,Blast Phase
HSCT

Interventions

DRUG: Enrolled patients with blast-phase chronic myeloid leukemia received a reduced-toxicity conditioning regimen containing thiotepa, melphalan, and fludarabine prior to undergoing allogeneic hematopoie

Sponsor

Institute of Hematology & Blood Diseases Hospital, China